Eli Lilly’s Alzheimer’s drug receives unanimous FDA panel support
An independent panel advising the FDA unanimously agreed that Eli Lilly's Alzheimer's treatment, donanemab, offers more benefits than risks. The decision paves the way for the FDA's final verdict, anticipated after a meeting prompted by divergent trial designs. Donanemab targets toxic plaques and showed promising effectiveness, with innovative trial features earning praise. While challenges remain, analysts foresee potential FDA approval, marking a significant advance in Alzheimer's therapeutics.
Sign up for your early morning brew of the BizNews Insider to keep you up to speed with the content that matters. The newsletter will land in your inbox at 5:30am weekdays. Register here.
By Bhanvi Satija and Julie Steenhuysen
Outside advisers to the U.S. Food and Drug Administration on Monday voted unanimously that the benefits of Eli Lilly's experimental Alzheimer's treatment donanemab outweighed its risks, and agreed that trial data showed it was effective in patients with an early stage of the memory-robbing disease.
___STEADY_PAYWALL___